Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

clinical investigation of the TLR7 mechanism in HCV by taking ANA773 into a clinical trial under a two-part protocol designed to test ANA773 in both healthy volunteers and patients with HCV. In October, Anadys completed dosing in healthy volunteers. Subjects received a single dose followed by four doses taken every other day, at levels from 200 mg to 1600 mg (with six subjects receiving active and two receiving placebo in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects beginning at 800 mg. Some side effects commonly seen with interferon treatment, including fever and chills, were observed at higher doses, with the frequency and intensity of interferon-like side effects increasing with dose. One subject at the 1200 mg dose and two subjects at the 1600 mg dose discontinued from the trial before completion of dosing. Anadys expects to initiate Part B of the study in HCV patients within the next few weeks. Patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort.

-- Phase I Clinical Trial of ANA773 in Oncology. Anadys continues to enroll patients in an ongoing Phase I clinical trial of ANA773 in oncology and has now completed enrollment in the third cohort.

Webcast of Conference Call

Anadys will host a conference call at 5:00 p.m. EDT today to discuss its third quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 86226986. The webcast and t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 According to a ... & 2D Gel Electrophoresis, Agarose & Polyacrylamide Gel, Capillary ... by Application & by End User - Global Forecast ... expected to reach around $1.98 Billion by 2020 with ... to 2020. Browse 226 ma ...
(Date:5/22/2015)... DALLAS , May 22, 2015 Baylor ... and the Translational Genomics Research Institute (TGen) in ... that will focus on accelerating early detection and treatments for ... science of both institutions will lead to new clinical trials ... therapies – bridging the gap from bench to bedside across ...
(Date:5/21/2015)... May 21, 2015 Specialty Pharmacy ... and been admitted to BPA Worldwide as a ... will track audience data for Specialty Pharmacy Times ... , “By becoming a member of BPA Worldwide, ... providing our clients with the most reliable, unequaled ...
(Date:5/21/2015)... CA (PRWEB) May 21, 2015 ... has announced a partnership with PicnicHealth, a healthcare ... patients. Participants diagnosed with Inflammatory Bowel Disease (IBD) ... as a complementary uBiome research kit. Both companies ... , For more information on ...
Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Specialty Pharmacy Times Joins BPA Worldwide 2uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3
... 2011 UCB, a leading biopharmaceutical company at the ... 2011 American College of Rheumatology (ACR) meeting by reinforcing ... and their healthcare providers. At this year,s ACR meeting, ... data with new findings on patient-reported quality of life ...
... SQNM ), a life sciences company providing innovative genetic ... third quarter of 2011, an increase of 16% compared to revenues ... for the third quarter of 2011 was $18.4 million or $0.19 ... $0.30 per share for the same period in 2010. ...
... NEW YORK, Nov. 3, 2011 Reportlinker.com announces ... in its catalogue: Global ... http://www.reportlinker.com/p0619270/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory INTRODUCTION  ... BCC,s goal for this study ...
Cached Biology Technology:UCB Reinforces Long-Standing Commitment to Rheumatology at American College of Rheumatology 2011 Annual Scientific Meeting 2UCB Reinforces Long-Standing Commitment to Rheumatology at American College of Rheumatology 2011 Annual Scientific Meeting 3UCB Reinforces Long-Standing Commitment to Rheumatology at American College of Rheumatology 2011 Annual Scientific Meeting 4Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 2Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 3Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 4Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 5Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 6Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 7Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 8Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Global Biochip Markets: Microarrays and Lab-on-a-Chip 5
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/14/2015)... 14, 2015 Research and Markets ( ... "Fingerprint Sensors Market in Smart Mobile Devices " ... that 2014 was a watershed year for fingerprint sensors ... ,Apple Pay,. Apple gave fingerprint sensors a raison d,etre ... Fingerprint sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... than a decade to understand how tiny molecules called ... that microRNA actually moves between cells to help them ... of cells that grow and develop. This discovery ... including medical gene therapy and bioengineering of crop plants. ...
... simplify lab-on-a-chip devices that could offer quicker, cheaper ... researchers have created microfluidic integrated circuits. Just ... electricity on computer chips without external controls, these ... their devices without instructions from outside systems. ...
... is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-04/sfeb-phr042210.php,">Chinese . ... with extraordinarily complex fluctuations across a wide range of ... both clinical and dynamical significance it may provide ... of the heart,s pacemaking system. In work published ...
Cached Biology News:Production of biofuels could benefit by controlling the types of cells that develop in plants 2Microfluidic integrated circuit could help enable home diagnostic tests 2Microfluidic integrated circuit could help enable home diagnostic tests 3Periodic heart rate decelerations in premature infants 2Periodic heart rate decelerations in premature infants 3
...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
Biology Products: